CoChat
Sign Up
Cited by 100Reproductive Health and ContraceptionEstrogen and related hormone effectsEffects and risks of endocrine disrupting chemicals

Unique effects on hepatic function, lipid metabolism, bone and growth endocrine parameters of estetrol in combined oral contraceptives

Open access
Mawet, Marie, Maillard, Catherine, Klipping, Christine, Zimmerman, Yvette, Foidart, Jean-Michel, Coelingh Bennink, Herjan J.T.·2015·The European Journal of Contraception & Reproductive Health Care
DOI 10.3109/13625187.2015.1068934PMC PMC4699469
Open this paper in CoChat — free accountOpen PDF

Abstract

Objectives Estetrol (E4) is a natural estrogen produced by the human fetal liver. In combination with drospirenone (DRSP) or levonorgestrel (LNG), E4 blocks ovulation and has less effect on haemostatic biomarkers in comparison with ethinylestradiol (EE) combined with DRSP. This study evaluates the impact of several doses of E4/DRSP and E4/LNG on safety parameters such as liver function, lipid metabolism, bone markers and growth endocrine parameters.Methods This was a dose-finding, single-centre, controlled study performed in healthy women aged 18 to 35 years with a documented pretreatment ovulatory cycle. Participants received 5 mg or 10 mg E4/3 mg DRSP; 5 mg, 10 mg or 20 mg E4/150 μg LNG; or 20 μg EE/3 mg DRSP as a comparator for three consecutive cycles in a 24/4-day regimen. Changes from baseline to end of treatment in liver parameters, lipid metabolism, bone markers and growth endocrinology were evaluated.Results A total of 109 women were included in the study. Carrier proteins were minimally affected in the E4/DRSP and E4/LNG groups, in comparison with the EE/DRSP group, where a significant increase in sex hormone-binding globulin was observed. Similarly, minor effects on lipoproteins were observed in the E4 groups, and the effects on triglycerides elicited by the E4 groups were significantly lower than those in the EE/DRSP group. No imbalances in bone markers were observed in any groups. No alterations in insulin-like growth factor were observed in the E4 groups.Conclusions E4-containing combinations have a limited effect on liver function, lipid metabolism, and bone and growth endocrine parameters.Chinese Abstract摘要目的 雌四醇（E4）是来源于人胎儿肝脏的天然雌激素。雌四醇与屈螺酮（DRSP)或左炔诺孕酮(LNG)配伍的复方口服避孕药制剂，能够抑制排卵，同时相较于炔雌醇(EE)与屈螺酮配伍制剂，它对凝血功能的各项指标影响较小。本研究的目的是为了评估不同剂量的雌四醇与屈螺酮以及左炔诺孕酮的配伍制剂对肝功能、脂代谢、骨骼转换标志物、以及生长激素分泌等安全性指标的影响。方法 本研究为开放的、单中心、剂量定义的对照研究，研究对象为18-35岁、具有良好的排卵周期的健康妇女，受试者分别接受5mg或10mg雌四醇/屈螺酮3mg(E4/DRSP)制剂，5mg、10mg、20mg雌四醇/左炔诺孕酮150ug(E4/LNG)制剂，以及20ug炔雌醇/屈螺酮(EE/DRSP)3mg制剂作为对照，连续三个24/4天周期。自基线到研究结束，测定肝功能、脂代谢、骨转换以及生长激素分泌的各项指标，对其改变进行评估。结果 109名妇女入选该研究。与EE/DRSP组比较，E4/DRSP以及E4/LNG组肝脏产生的运载蛋白受影响很小，但是EE/DRSP组性激素结合蛋白的含量明显增加。同样，E4组的脂蛋白受影响很小，而且对甘油三酯的影响显著低于EE/DRSP组。在所有研究组中，都没有观察到骨转换的失衡。在E4组，没有观察到胰岛素样生长因子的改变。结论 含有E4的复方制剂对肝功能、脂代谢、骨骼转换以及生长内分泌的影响有限。关键词 骨标记物、屈螺酮、内分泌、雌四醇、左炔诺孕酮、脂代谢、肝功能

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3109/13625187.2015.1068934

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • E4 (alone or in combination with DRSP) has limited effects on liver function and metabolic and endocrine parameters when used in doses up to 10 mg and for less than 3 months.

    “E4 (alone or in combination with DRSP) has limited effects on liver function and metabolic and endocrine parameters when used in doses up to 10 mg and for less than 3 months [ 14 , 15 ].”

    From Endocrine and metabolic effects of an oral contraceptive containing estetrol and drospirenone (2021) · cites this paper as [14]

    The Conclusion reports limited effects on liver function, lipid metabolism, and bone and growth endocrine parameters for E4/DRSP compared with EE/DRSP. The Methods (Treatment and study design; page unavailable) specify 5 mg and 10 mg E4/DRSP over three 28-day cycles. The paper did not study E4 alone, so it does not support the monotherapy part of the claim. (LLM, conf=0.88)

    Experimental — accuracy not yet measured

  • EE/DRSP increased HDL-C slightly and EE/LNG decreased HDL-C, which is in line with previous studies.

    “EE/DRSP increased HDL-C slightly and EE/LNG decreased HDL-C, which is in line with previous studies [ 14 , 16 ].”

    From Endocrine and metabolic effects of an oral contraceptive containing estetrol and drospirenone (2021) · cites this paper as [14]

    The Liver Function and Lipid Metabolism section reports a 15.2% increase in HDL-C with EE/DRSP, and the Discussion says this agrees with prior literature. The decrease reported here was with E4/LNG, not EE/LNG; this study did not test EE/LNG. (LLM, conf=0.90)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 44

  1. Westhoff CL Heartwell S Edwards S et al Oral contraceptive discontinuation: Do side effects matter? Am J Obstet Gynecol 2007 196 412 17403440 PMC1903378
  2. Bitzer J Pharmacological profile of estrogens in oral contraception Minerva Ginecol 2011 63 299 304 21654614
  3. Cirillo DJ Wallace RB Rodabough RJ et al Effect of estrogen therapy on gallbladder disease JAMA 2005 293 330 9 15657326
  4. Kiley J Hammond C Combined oral contraceptives: A comprehensive review Clin Obstet Gynecol 2007 50 868 77 17982329
  5. Stegeman BH de Bastos M Rosendaal FR et al Different combined oral contraceptives and the risk of venous thrombosis: Systematic review and network meta-analysis BMJ 2013 347 f5298 24030561 PMC3771677
  6. Rosenberg MJ Meyers A Roy V Efficacy, cycle control, and side effects of low- and lower-dose oral contraceptives: A randomized trial of 20 micrograms and 35 micrograms estrogen preparations Contraception 1999 60 321 9 10715366
  7. Hoffmann H Moore C Zimmermann H et al Approaches to the replacement of ethinylestradiol by natural 17beta-estradiol in combined oral contraceptives Exp Toxicol Pathol 1998 50 458 64 9784023
  8. Coelingh Bennink F Holinka CF Visser M et al Maternal and fetal estetrol levels during pregnancy Climacteric 2008 11 (Suppl.1) 69 72 18464026
  9. Visser M Coelingh Bennink HJ Clinical applications for estetrol J Steroid Biochem Mol Biol 2009 114 85 9 19167495
  10. Abot A Fontaine C Buscato M et al The uterine and vascular actions of estetrol delineate a distinctive profile of estrogen receptor alpha modulation, uncoupling nuclear and membrane activation EMBO Mol Med 2014 6 1328 46 25214462 PMC4287935
  11. Adlanmerini M Solinhac R Abot A et al Mutation of the palmitoylation site of estrogen receptor alpha in vivo reveals tissue-specific roles for membrane versus nuclear actions Proc Natl Acad Sci U S A 2014 111 283 90 PMC3896153 24371309
  12. Coelingh Bennink HJ Holinka CF Diczfalusy E Estetrol review: profile and potential clinical applications Climacteric 2008 11 (Suppl.1) 47 58 18464023
  13. Coelingh Bennink HJ Skouby S Bouchard P et al Ovulation inhibition by estetrol in an in vivo model Contraception 2008 77 186 90 18279689
  14. World Health Organization Combined hormonal contraceptives (CHCs) Medical eligibility criteria for contraceptive use 4th edn Geneva WHO 2010 15 44 23741782
  15. Rikken B van Doorn J Ringeling A et al Plasma levels of insulin-like growth factor (IGF)-I, IGF-II and IGF-binding protein-3 in the evaluation of childhood growth hormone deficiency Horm Res 1998 50 166 76 9762006
  16. de Boer L Hoogerbrugge CM van Doorn J et al Plasma insulin-like growth factors (IGFs), IGF-binding proteins (IGFBPs), acid-labile subunit (ALS) and IGFBP-3 proteolysis in individuals with clinical characteristics of Sotos syndrome J Pediatr Endocrinol Metab 2004 17 615 27 15198293
  17. de Vries BB Robinson H Stolte-Dijkstra I et al General overgrowth in the fragile X syndrome: Variability in the phenotypic expression of the FMR1 gene mutation J Med Genet 1995 32 764 9 8558551 PMC1051696
  18. Gyulikhandanova NE Tsymbalenko NV Platonova NA et al Regulation of ceruloplasmin gene in mammals Bull Exp Biol Med 2004 137 485 9 15455125
  19. De Groote D Perrier d’Hauterive S Pintiaux A et al Effects of oral contraception with ethinylestradiol and drospirenone on oxidative stress in women 18–35 years old Contraception 2009 80 187 93 19631796
  20. Odlind V Milsom I Persson I et al Can changes in sex hormone binding globulin predict the risk of venous thromboembolism with combined oral contraceptive pills? Acta Obstet Gynecol Scand 2002 81 482 90 12047300
  21. Raps M Helmerhorst F Fleischer K et al Sex hormone-binding globulin as a marker for the thrombotic risk of hormonal contraceptives J Thromb Haemost 2012 10 992 7 22469296
  22. Stegeman BH Helmerhorst FM Vos HL et al Sex hormone-binding globulin levels are not causally related to venous thrombosis risk in women not using hormonal contraceptives J Thromb Haemost 2012 10 2061 7 22882730
  23. Kluft C Skouby SO Jespersen J et al Sex hormone-binding globulin as a marker for the thrombotic risk of hormonal contraceptives: A rebuttal J Thromb Haemost 2013 11 394 5 23140257
  24. Raps M Helmerhorst FM Fleischer K et al Sex hormone-binding globulin as a marker for the thrombotic risk of hormonal contraceptives: reply to a rebuttal J Thromb Haemost 2013 11 396 7 23176323
  25. Akhter S Shamsuzzaman AK Banarjee M et al Serum copper in rural women taking combined oral contraceptive Mymensingh Med J 2006 15 25 9 16467758
  26. Berg G Kohlmeier L Brenner H Effect of oral contraceptive progestins on serum copper concentration Eur J Clin Nutr 1998 52 711 5 9805216
  27. Benes B Spevackova V Smid J et al Effects of age, BMI, smoking and contraception on levels of Cu, Se and Zn in the blood of the population in the Czech Republic Cent Eur J Public Health 2005 13 202 7 16419386
  28. Agren UM Anttila M Maenpaa-Liukko K et al Effects of a monophasic combined oral contraceptive containing nomegestrol acetate and 17beta-oestradiol compared with one containing levonorgestrel and ethinylestradiol on haemostasis, lipids and carbohydrate metabolism Eur J Contracept Reprod Health Care 2011 16 444 57 22066891 PMC3233272
  29. Sitruk-Ware R Pharmacology of different progestogens: The special case of drospirenone Climacteric 2005 8(Suppl 4 12 16203650
  30. Endrikat J Klipping C Cronin M et al An open label, comparative study of the effects of a dose-reduced oral contraceptive containing 20 microg ethinyl estradiol and 100 microg levonorgestrel on hemostatic, lipids, and carbohydrate metabolism variables Contraception 2002 65 215 21 11929643
  31. Scharnagl H Petersen G Nauck M et al Double-blind, randomized study comparing the effects of two monophasic oral contraceptives containing ethinylestradiol (20 microg or 30 microg) and levonorgestrel (100 microg or 150 microg) on lipoprotein metabolism Contraception 2004 69 105 13 14759614
  32. Skouby SO Endrikat J Dusterberg B et al A 1-year randomized study to evaluate the effects of a dose reduction in oral contraceptives on lipids and carbohydrate metabolism: 20 microg ethinyl estradiol combined with 100 microg levonorgestrel Contraception 2005 71 111 7 15707560
  33. Tuppurainen M Klimscheffskij R Venhola M et al The combined contraceptive vaginal ring (NuvaRing) and lipid metabolism: A comparative study Contraception 2004 69 389 94 15105061
  34. Hurwitz BE Henry N Goldberg RB Long-term oral contraceptive treatment, metabolic syndrome and measures of cardiovascular risk in pre-menopausal women: National Health and Nutrition Examination Survey 1999–2004 Gynecol Endocrinol 2009 25 441 9 19499415
  35. Coelingh Bennink HJ Heegaard AM Visser M et al Oral bioavailability and bone-sparing effects of estetrol in an osteoporosis model Climacteric 2008 11 (Suppl. 1) 2 14 18464016
  36. Delmas PD Biochemical markers of bone turnover for the clinical assessment of metabolic bone disease Endocrinol Metab Clin North Am 1990 19 1 18 2192865
  37. Rosen HN Moses AC Garber J et al Serum CTX: A new marker of bone resorption that shows treatment effect more often than other markers because of low coefficient of variability and large changes with bisphosphonate therapy Calcif Tissue Int 2000 66 100 3 10652955
  38. Di Carlo C Gargano V Sparice S et al Short-term effects of an oral contraceptive containing oestradiol valerate and dienogest on bone metabolism and bone mineral density: An observational, preliminary study Eur J Contracept Reprod Health Care 2013 18 388 93 23859010
  39. Massaro M Di Carlo C Gargano V et al Effects of the contraceptive patch and the vaginal ring on bone metabolism and bone mineral density: A prospective, controlled, randomized study Contraception 2010 81 209 14 20159176
  40. Balogh A Kauf E Vollanth R et al Effects of two oral contraceptives on plasma levels of insulin-like growth factor I (IGF-I) and growth hormone (hGH) Contraception 2000 62 259 69 11172797
  41. Weissberger AJ Ho KK Lazarus L Contrasting effects of oral and transdermal routes of estrogen replacement therapy on 24 h growth hormone (GH) secretion, insulin-like growth factor I, and GH-binding protein in postmenopausal women J Clin Endocrinol Metab 1991 72 374 81 1991807
  42. Thijs C Knipschild P Oral contraceptives and the risk of gallbladder disease: A meta-analysis Am J Public Health 1993 83 1113 20 8342719 PMC1695167
  43. Gargano V Massaro M Morra I et al Effects of two low-dose combined oral contraceptives containing drospirenone on bone turnover and bone mineral density in young fertile women: A prospective controlled randomized study Contraception 2008 78 10 5 18555812
  44. Paoletti AM Orru M Lello S et al Short-term variations in bone remodeling markers of an oral contraception formulation containing 3 mg of drospirenone plus 30 microg of ethinyl estradiol: Observational study in young postadolescent women Contraception 2004 70 293 8 15451333

Cited by

Sorted by citations

Authors
Mawet, M., Maillard, C., Klipping, C., Zimmerman, Y., Foidart, J.-M., & Coelingh Bennink, H. J. T.
Affiliations
  • *Estetra SPRL, Liège, Belgium
  • Dinox BV, Groningen, the Netherlands
  • Pantarhei Bioscience (Netherlands) (NL)
  • University of Liège (BE)
  • Pantarhei Bioscience BV, Zeist, the Netherlands
Corresponding author
Mawet, Marie
ORCID
Venue
The European Journal of Contraception & Reproductive Health Care
Publisher
Informa UK Limited
Published
2015-07-27
Volume
20
Issue
6
Pages
463-475
ISSN
  • 1362-5187 (ISSN-L)
  • 1473-0782
DOI
10.3109/13625187.2015.1068934
PMC
PMC4699469
OpenAlex
W1722228117
Cited by
100
References
3
Citations by year
2026: 7 · 2025: 7 · 2024: 15 · 2023: 25 · 2022: 10 · 2021: 14 · 2020: 4 · 2019: 3 · 2018: 4 · 2017: 5 · 2016: 5 · 2015: 1
FWCI
5.36
Type
journal article
Language
en
Open access
Locations
  • The European Journal of Contraception & Reproductive Health Care (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • ORBi (University of Liège) (submittedVersion)
  • PubMed
Topics
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Reproductive Health and Contraception
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Estrogen and related hormone effects
  • Physical Sciences › Environmental Science › Health, Toxicology and Mutagenesis › Effects and risks of endocrine disrupting chemicals
Keywords
estetrol, E4, drospirenone, levonorgestrel, ethinyl estradiol, combined oral contraceptives, liver function, lipid metabolism, sex hormone-binding globulin, lipoproteins, triglycerides, bone turnover markers, insulin-like growth factor, dose comparison, ovulation inhibition
MeSH terms
Adolescent, Adult, Mineralocorticoid Receptor Antagonists, Alkaline Phosphatase, Androstenes, Aspartate Aminotransferases, Contraceptives, Oral, Combined, Contraceptives, Oral, Synthetic, Estetrol, Estrogens, Ethinyl Estradiol, Female, gamma-Glutamyltransferase, Humans, Insulin-Like Growth Factor I, Insulin-Like Growth Factor II, Cholesterol, HDL, Cholesterol, LDL, Liver, Peptides, Sex Hormone-Binding Globulin, Growth Hormone, Triglycerides, Osteocalcin, Levonorgestrel, Collagen Type I, Lipid Metabolism, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review